[go: up one dir, main page]

BR9913652A - Gene e proteìna antigênica imunodominante de 120 kda de ehrlichia canis - Google Patents

Gene e proteìna antigênica imunodominante de 120 kda de ehrlichia canis

Info

Publication number
BR9913652A
BR9913652A BR9913652-0A BR9913652A BR9913652A BR 9913652 A BR9913652 A BR 9913652A BR 9913652 A BR9913652 A BR 9913652A BR 9913652 A BR9913652 A BR 9913652A
Authority
BR
Brazil
Prior art keywords
protein
ehrlichia canis
kda
canis
gene
Prior art date
Application number
BR9913652-0A
Other languages
English (en)
Other versions
BR9913652B1 (pt
Inventor
David H Walker
Xu-Jie Yu
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of BR9913652A publication Critical patent/BR9913652A/pt
Publication of BR9913652B1 publication Critical patent/BR9913652B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Patente de Invenção: <B>"GENE E PROTEìNA ANTIGêNICA IMUNODOMINANTE DE 120 KDA DE EHRLICHIA CANIS"<D>. A presente invenção provê um gene de proteína de 120 kDa de Ehrlichia canis, ampliado por PCR usando-se iniciadores derivados das seq³ências de DNA que flanqueiam o gene de proteína de 120 kDa de Ehrlichia chaffeensis. A proteína de 120 kDa de Ehrlichia canis recombinante contém 14 unidades de repetição tandem com 36 aminoácidos cada. As unidades de repetição são hidrofílicas e são preditas ser de superfície exposta. Também revelado é que a proteína de 120 kDa de E. canis recombinante é antigênica e reage com soros oriundos de cachorros convalescentes de erliquiose canina.
BRPI9913652-0A 1998-08-27 1999-08-27 Vetor compreendendo sequência de Ehrlichia canis, bem como microoganismo transgênico BR9913652B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/141,047 US6043085A (en) 1998-08-27 1998-08-27 Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US09/141,047 1998-08-27
PCT/US1999/019538 WO2000012688A1 (en) 1998-08-27 1999-08-27 Ehrlichia canis 120-kda immunodominant antigenic protein and gene

Publications (2)

Publication Number Publication Date
BR9913652A true BR9913652A (pt) 2001-06-05
BR9913652B1 BR9913652B1 (pt) 2014-02-18

Family

ID=22493934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9913652-0A BR9913652B1 (pt) 1998-08-27 1999-08-27 Vetor compreendendo sequência de Ehrlichia canis, bem como microoganismo transgênico

Country Status (17)

Country Link
US (1) US6043085A (pt)
EP (1) EP1108014B1 (pt)
JP (1) JP4550998B2 (pt)
KR (1) KR100652469B1 (pt)
CN (1) CN1281747C (pt)
AT (1) ATE328073T1 (pt)
AU (1) AU764853B2 (pt)
BR (1) BR9913652B1 (pt)
CA (1) CA2340462A1 (pt)
DE (1) DE69931639D1 (pt)
IL (2) IL141613A0 (pt)
MX (1) MXPA01002042A (pt)
NZ (1) NZ510103A (pt)
RU (1) RU2232814C2 (pt)
TW (1) TW557326B (pt)
WO (1) WO2000012688A1 (pt)
ZA (1) ZA200101440B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115840A1 (en) * 1998-11-30 2002-08-22 Walker David H. Homologous 28-kilodaltion immunodominant protein genes of Ehrlichia canis and uses thereof
US6392023B1 (en) * 1999-03-03 2002-05-21 Research Development Foundation Homologous 28-kilodalton immunodominant protein genes of Ehrlicha canis and uses thereof
US7335754B2 (en) * 1999-07-21 2008-02-26 Cornell Research Foundation, Inc. Ehrlichia canis genes and vaccines
US6355777B1 (en) * 2000-04-28 2002-03-12 Research Development Foundation P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
CA2407946A1 (en) * 2000-05-01 2001-11-08 Research Development Foundation Ehrlichia chaffeensis 28 kda outer membrane protein multigene family
ATE372378T1 (de) * 2002-11-04 2007-09-15 Res Dev Foundation P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7842474B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
AU2006231473B2 (en) * 2005-04-04 2012-01-12 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
ES2618842T3 (es) 2007-09-11 2017-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vacuna atenuada para la erliquiosis
WO2009039413A2 (en) 2007-09-21 2009-03-26 Idexx Laboratories, Inc. Methods and compositions for detection of ehrlichia chaffeensis (p120)
CN101970463A (zh) 2007-09-21 2011-02-09 艾德克斯实验室公司 用于检测恰菲埃里希氏体(vlpt)的方法和组合物
EP2045816A1 (en) * 2007-10-01 2009-04-08 Paul Scherrer Institut Fast readout method and swiched capacitor array circuitry for waveform digitizing
CZ2007716A3 (cs) 2007-10-15 2009-04-29 Elmarco S. R. O. Zpusob výroby nanovláken
EP3527221B1 (en) * 2007-10-31 2022-02-23 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
KR101010432B1 (ko) * 2008-08-30 2011-01-21 이영수 여과기
DK2424880T3 (en) 2009-04-28 2016-10-24 Res Dev Foundation Immunoreactive Ehrlichia p120 / p140 epitopes, and uses thereof
KR101892182B1 (ko) * 2009-11-20 2018-08-24 아박시스, 인크. 에를리키아 항체의 검출을 위한 펩티드, 장치 및 방법
KR101858770B1 (ko) * 2010-07-02 2018-05-16 인터벳 인터내셔널 비.브이. 에를리키아 카니스에 대한 백신
US9651546B2 (en) 2012-10-11 2017-05-16 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
US9442112B2 (en) * 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
CA3107319A1 (en) * 2018-07-27 2020-01-30 Research Development Foundation Chimeric immunogenic polypeptides
BR112022000347A2 (pt) * 2019-07-12 2022-04-12 Res Found Dev Vacinas de ehrlichia e composições imunogênicas

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015691A (en) * 1996-05-31 2000-01-18 Research Development Foundation Immunodominant 120 kDa surface-exposed adhesion protein genes of Ehrlichia chaffeensis

Also Published As

Publication number Publication date
IL141613A (en) 2010-05-31
EP1108014B1 (en) 2006-05-31
NZ510103A (en) 2004-10-29
JP4550998B2 (ja) 2010-09-22
IL141613A0 (en) 2002-03-10
DE69931639D1 (en) 2006-07-06
TW557326B (en) 2003-10-11
EP1108014A4 (en) 2004-12-15
ZA200101440B (en) 2002-01-30
RU2232814C2 (ru) 2004-07-20
AU764853B2 (en) 2003-09-04
ATE328073T1 (de) 2006-06-15
EP1108014A1 (en) 2001-06-20
KR20010072997A (ko) 2001-07-31
JP2002523087A (ja) 2002-07-30
CN1281747C (zh) 2006-10-25
CN1321190A (zh) 2001-11-07
US6043085A (en) 2000-03-28
CA2340462A1 (en) 2000-03-09
WO2000012688A1 (en) 2000-03-09
BR9913652B1 (pt) 2014-02-18
KR100652469B1 (ko) 2006-12-01
MXPA01002042A (es) 2002-06-21
AU5586499A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
BR9913652A (pt) Gene e proteìna antigênica imunodominante de 120 kda de ehrlichia canis
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
ATE491471T1 (de) Adjuvantien für dns impstoffe basierend auf imidazochinoline
PT783321E (pt) Sequencia nucleotidica viral vr-2332 e metodos de utilizacao
DK2228440T3 (da) Varianter af beta-glucosidaser
BR122016004546B8 (pt) vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
BRPI0211191B8 (pt) ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios
BR0312276A (pt) Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
DK1007686T3 (da) Tuberkulosevaccine
BRPI0407207A (pt) Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter
BRPI0403221A (pt) Fragmento de taq polimerase termoestável
BRPI0409789A (pt) vacina de tuberculose com eficácia aperfeiçoada
PT1219711E (pt) Vacina de lawsonia intracellularis
BRPI0612288A2 (pt) amilase modificada de pseudomonas saccharophilia
ATE447612T1 (de) Fluoreszenzproteine
ATE541944T1 (de) Polynukleotidprimer
BR0011469A (pt) Gm-csf equina
FR2828405B1 (fr) Vaccin anti-coronavirus
TW200716166A (en) Lawsonia intracellularis immunological proteins
PE20061441A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
EP1602721A4 (en) KOJI MILK PHOSPHOLIPASE A2
DK0778894T3 (da) Vaccine mod infektiös felin peritonitis
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.